TNYA — Tenaya Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1858848 ·
Last close
$0.67
Market Cap
$151.29M
52W High
$0.95
52W Low
$0.66
ADV30
1,994,825
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,110,000 | — | -20,899,000 | -43,393,000 | 93,540,000 | 78,085,000 | 24,131,000 |
| Mar 2026 | 225,000 | — | -20,065,000 | -19,272,000 | 135,070,000 | 80,887,000 | 28,881,000 |
| Dec 2025 | 0 | — | -20,775,000 | -20,175,000 | 146,921,000 | 100,547,000 | 23,656,000 |
| Sep 2025 | 0 | — | -20,936,000 | -20,275,000 | 104,980,000 | 56,312,000 | 22,112,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-52,325,000
Investing CF
$8,623,000
Financing CF
$59,116,000
CapEx
$-263,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.53
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-667,673,000
Inventory
—
Receivables
$371,000
ST Investments
$0
EBIT TTM
$-82,675,000
Pretax Income TTM
$-103,115,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,335,000
EBITDA
$-75,524,000
Free Cash Flow
$-32,600,500
Enterprise Value
$82,219,584
Total Cash
$78,085,000
Total Debt
$3,949,000
Shares Out
224,230,012
Trailing EPS
$-0.51
Book Value
$0.49
ROE
-121.9%
ROA
-47.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -93,331,000 | -90,597,000 | 146,921,000 | 23,656,000 | — | -68,264,000 |
| Dec 2024 | 0 | -115,948,000 | -111,129,000 | 119,940,000 | 27,086,000 | — | -90,501,000 |
| Dec 2023 | 0 | -131,193,000 | -124,084,000 | 170,515,000 | 31,091,000 | — | -102,072,000 |
| Dec 2022 | 0 | -125,621,000 | -123,665,000 | 278,945,000 | 35,569,000 | — | -104,424,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.39
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $0.68 · call volume: 41 · put volume: 81
Expected Move to 2027-01-15:
±$0.60
(88.89%) —
implied range
$0.08 –
$1.28
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OTLK | Outlook Therapeutics, Inc. | $147.79M | $0.61 | — |
| LENZ | LENZ Therapeutics, Inc. | $144.22M | $4.59 | — |
| MOLN | MOLECULAR PARTNERS AG | $165.05M | $4.40 | — |
| CRBU | Caribou Biosciences, Inc. | $175.82M | $1.64 | — |
| HUMA | Humacyte, Inc. | $183.96M | $0.66 | — |
News headlines (Yahoo Finance, 1h cache)
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301
2026-08-18 08:01 · Yahoo
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-05 20:05 · Yahoo
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2026-07-15 01:00 · Yahoo
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
2026-06-29 12:30 · Yahoo
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sympt
2026-06-03 11:00 · Yahoo
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
2026-06-02 20:30 · Yahoo
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
2026-05-29 12:00 · Yahoo
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
2026-08-04 20:05 · Yahoo
Exploring 3 High Growth Tech Stocks In The US Market
2026-06-05 17:38 · Yahoo
US High Growth Tech Stocks with Promising Potential
2026-06-05 11:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.